[Form 4] Eli Lilly & Co. Insider Trading Activity

Rhea-AI Filing Summary

Daniel Skovronsky, EVP, Chief Scientific Officer and President of LRL & LLY Imm at Eli Lilly & Co (LLY), reported a purchase on 08/12/2025 of 1,000 shares of common stock on Form 4. The transaction is coded P for purchase at a weighted average price of $634.405 with execution prices ranging from $634.21 to $634.42. After the reported purchase the filing shows 137,660.112 shares beneficially owned directly. The filing also discloses indirect holdings of 72,359 shares by a trust, 747 shares by the reporting person’s spouse, and 2,510 shares held in a spousal lifetime access trust transferred on March 10, 2025. The filer disclaims beneficial ownership except to the extent of pecuniary interest.

Insights

Financial Analyst

TL;DR Insider purchase of 1,000 shares increases direct holdings modestly; transaction is disclosed at a weighted average price of $634.405.

The Form 4 documents a P purchase of 1,000 shares on 08/12/2025 at a weighted average price of $634.405. Following the purchase the reporting person’s direct beneficial ownership is listed as 137,660.112 shares. The filing itemizes additional indirect holdings by trust and spouse. From a financial-analyst perspective this is a routine officer purchase disclosed under Section 16 and provides transparent detail on price range and holdings; the size of the purchase is small relative to the absolute number of shares reported as owned.

Corporate Governance Expert

TL;DR Disclosure includes appropriate footnotes and indirect-ownership detail; the Form 4 appears complete and properly executed.

The filing includes clarifying footnotes: a weighted average price range for the purchase, a disclaimer of beneficial ownership except for pecuniary interest, and a note that 2,510 shares were transferred to a spousal lifetime access trust on March 10, 2025. The form is signed by an authorized filer. No derivative transactions are reported. The disclosures address indirect ownership channels and trustee arrangements, consistent with Section 16 reporting expectations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Skovronsky Daniel

(Last) (First) (Middle)

LILLY CORPORATE CENTER

(Street)

INDIANAPOLIS IN 46285

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CSO & Pres. LRL & LLY Imm

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		P		1,000	A	$634.405(1)	137,660.112	D
Common Stock								72,359	I	By Trust(2)
Common Stock								747(3)	I	By spouse(2)
Common Stock								2,510	I	By spouse's SLAT(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $634.21 to $634.42, inclusive. The reporting person undertakes to provide to Eli Lilly and Company, any security holder of Eli Lilly and Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

3. On March 10, 2025, the Reporting Person's spouse transferred 2,510 shares of Eli Lilly and Company common stock to a spousal lifetime access trust, of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and children are beneficiaries.

Remarks:

	/s/ Jonathan Groff for Daniel Skovronsky, pursuant to authorization on file	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Daniel Skovronsky report on Form 4 for LLY?

The filing reports a purchase of 1,000 shares on 08/12/2025 coded P at a weighted average price of $634.405.

How many Eli Lilly shares does the reporting person own after the transaction?

The Form 4 shows 137,660.112 shares beneficially owned directly following the reported transaction.

Are there any indirect holdings disclosed for Daniel Skovronsky?

Yes. The filing discloses 72,359 shares held by a trust, 747 shares by the spouse, and 2,510 shares in a spousal lifetime access trust.

What price range was reported for the purchased shares?

The weighted average price is $634.405, and the execution prices ranged from $634.21 to $634.42.

What is the reporting person’s role at Eli Lilly?

The reporting person is listed as EVP, CSO & Pres. LRL & LLY Imm on the Form 4.